RPRX neurimmune sells a portion of its Royalty interest in cliramitug to Royalty Pharma Neurimmune: sold portion of its Royalty interest in
RPRX neurimmune sells a portion of its Royalty interest in cliramitug to Royalty Pharma Neurimmune: sold portion of its Royalty interest in cliramitug to Royalty Pharma for up to $425M - In Q1 of 2027, Royalty Pharma will provide another $125M in cash to Co
Story updates
11:05:05 AM UTC
SquawkNews
RPRX - Royalty Pharma acquires royalty interest in AstraZeneca’s cliramitug for up to $425 million from Neurimmune
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.